Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement “for diagnostic use only, in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualisation of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
VUEWAY should be used only when diagnostic information is essential and not available with unenhanced MRI”.
Clinical Benefit
| Substantial |
The clinical benefit of VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection is substantial in the MA indications. |
Clinical Added Value
| no clinical added value |
Considering:
- evidence of a non-inferiority of MRI with injection of VUEWAY (gadopiclenol) at a dose of 0.05 mmol/kg compared to injection of gadobutrol at a dose of 0.1 mmol/kg, on 3 coprimary endpoints for visualisation of lesions in the CNS and body, in the PICTURE and PROMISE studies conducted in adults,
- the pharmacokinetic profile in children similar to that observed in adults,
but:
- the absence of comparison in the paediatric study and robust efficacy and safety data,
- the limited safety data in terms of follow-up duration, limiting monitoring of the occurrence of adverse events (AE) such as retention of gadolinium in the brain or nephrogenic systemic fibrosis (NSF), an AE associated with the administration of a gadolinium-based contrast agent, the symptoms of which can develop several weeks to several months after its administration,
the Committee deems that VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection provides no clinical added value (CAV V) compared with gadobutrol. |
Avis rectifié en date du 26/11/2024
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
d8YXNbHt17vb6NvF
